Evidence map›Paper›PMID 36473155›Full record

ArticleOncotarget2022

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.

Yehia I Mohamed, Dan G Duda, Muhammad O Awiwi, Sunyoung S Lee, Lina Altameemi, Lianchun Xiao, Jeffrey S Morris, Robert A Wolff, Khaled M Elsayes, Rikita I Hatia and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Yehia I MohamedDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dan G DudaSteele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Muhammad O AwiwiDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sunyoung S LeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lina AltameemiHurley Medical Center, Michigan State University, East Lansing, MI 48824, USA.
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jeffrey S MorrisDepartment of Biostatistics, Epidemiology, and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Khaled M ElsayesDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rikita I HatiaDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aliya QayyumDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shadi M ChamseddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
James C YaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Armeen MahvashDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA.
Manal M HassanDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ahmed Omar KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USHarvard University · USMichigan State University · USUniversity of Pennsylvania · US

Funding

The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular CarcinomaP50CA217674 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YAO, JAMES C · 2019 to 2023
$11.3M
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC PatientsR01CA260872 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M, DUDA, DAN GABRIEL · 2021 to 2025
$3.0M
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapyR01CA260857 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Dan Gabriel Duda, Anand T.N. Kumar · 2021 to 2026
$2.7M
Vascularized tumor explants for drug testingR01CA247441 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L. · 2021 to 2025
$1.9M
Bayesian Network-Based Integrative Genomics Methods for Precision MedicineR01CA244845 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BALADANDAYUTHAPANI, VEERABHADRAN, MORRIS, JEFFREY S · 2021 to 2024
$1.8M
NCI NIH HHS P50 CA217674NCI NIH HHS R01 CA244845NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA260857
6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) has limited systemic therapy options when discovered at an advanced stage. Thus, there is a need for accessible and minimally invasive biomarkers of response to guide the selection of patients for treatment. This study investigated the biomarker value of plasma growth hormone (GH) level as a potential biomarker to predict outcome in unresectable HCC patients treated with current standard therapy, atezolizumab plus bevacizumab (Atezo/Bev). MATERIALS AND

methodsStudy included unresectable HCC patients scheduled to receive Atezo/Bev. Patients were followed to determine progression-free survival (PFS) and overall survival (OS). Plasma GH levels were measured by ELISA and used to stratify the HCC patients into GH-high and GH-low groups (the cutoff normal GH levels in women and men are ≤3.7 μg/L and ≤0.9 μg/L, respectively). Kaplan-Meier method was used to calculate median OS and PFS and Log rank test was used to compare survival outcomes between GH-high and -low groups.

resultsThirty-seven patients were included in this analysis, of whom 31 were males and 6 females, with a median age of 67 years (range: 37-80). At the time of the analysis, the one-year survival rate was 70% (95% CI: 0.51, 0.96) among GH low patients and 33% (95% CI: 0.16, 0.67) among GH high patients. OS was significantly superior in GH-low compared to GH-high patients (median OS: 18.9 vs. 9.3 months; DISCUSSION AND

conclusionsPlasma GH is a biomarker candidate for predicting treatment outcomes in advanced HCC patients treated with Atezo/Bev. This finding should be further validated in larger randomized clinical trials in advanced HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overBevacizumabFemaleGrowth HormoneHumansMiddle AgedBevacizumabGrowth Hormoneatezolizumabbevacizumabgrowth hormonehepatocellular carcinomaimmunotherapy

Identifiers

PMID36473155
PMCPMC9726202
OpenAlexW4311649105

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.